Soussi T

Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies.

Rodriguez L, Delhommeau F, Soussi T

Leukemia 39 (12) 3054-3055 [2025-12-00; online 2025-09-28]

A novel PML germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia.

Soussi T, Kundu S, Gerbaud P, ..., Sjöblom T, Baliakas P

Br. J. Haematol. 207 (3) 1118-1121 [2025-09-00; online 2025-07-07]

The TP53 tumor suppressor gene: From molecular biology to clinical investigations.

Baliakas P, Soussi T

J. Intern. Med. 298 (2) 78-96 [2025-08-00; online 2025-06-16]

Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.

Funk JS, Klimovich M, Drangenstein D, ..., Joerger AC, Stiewe T

Nat. Genet. 57 (1) 140-153 [2025-01-00; online 2025-01-07]

Letter to the editor.

Soussi T

Hum. Mol. Genet. 32 (13) 2121-2123 [2023-06-19; online 2023-03-11]

The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots.

Lazarian G, Leroy B, Theves F, ..., Soussi T, French Innovative Leukemia Organization (FILO)

Hum. Mutat. 2023 (-) 4880113 [2023-05-09; online 2023-05-09]

TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.

Lazarian G, Theves F, Hormi M, ..., Soussi T, French Innovative Leukemia Organisation (FILO)

Am. J. Hematol. 97 (4) E159-E162 [2022-04-00; online 2022-02-01]

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Malcikova J, Tausch E, Rossi D, ..., Pospisilova S, European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network

Leukemia 32 (5) 1070-1080 [2018-05-00; online 2018-02-02]